Conditions: Lung Neoplasms
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 41
Healthy volunteers: no

Brief summary:
The purpose of this study is to help answer:

* Whether pemetrexed, gemcitabine and/or carboplatin can shrink tumor(s) or make tumor(s) disappear in patients with relapsed lung cancer (lung cancer that has come back after surgical removal and chemotherapy), and to determine how long this will last
* Whether pemetrexed, gemcitabine and/or carboplatin can help patients with relapsed lung cancer live longer

Detailed description:

Arms:
arm 1: Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy arm 2: Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy arm 3: Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy arm 4: Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy

Interventions: intervention 1: pemetrexed intervention 2: gemcitabine intervention 3: carboplatin intervention 4: Pemetrexed
Intervention descriptions: intervention 1: 500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression intervention 2: 1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression intervention 3: area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression intervention 4: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression

Protocol document: